(Reuters) – Drugmaker Alexion Pharmaceuticals Inc said it would buy Synageva BioPharma Corp for $8.4 billion to boost its rare drug pipeline. Alexion’s cash-and-stock offer values Synageva at $225.92 per share — more than double of Synageva closing price of $95.87 on Tuesday. Synageva’s shares were trading at $216 before the bell on Wednesday, while […]
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
May 6 (Reuters) – GlaxoSmithKline laid out growth targets for its biggest businesses on Wednesday, hoping to convince investors that focusing on consumer health and vaccines would return the drugmaker to long-term growth. It also scrapped plans to float its HIV drug business ViiV Healthcare, citing its strong outlook. Chief Executive Andrew Witty is under […]
Drugmaking behemoth Pfizer Inc. (PFE) had some important information hidden in between the layers Of its first quarter conference call, said a columnist at The Motley Fool on Wednesday, and investors would be wise to take a closer look before parsing out the company’s value. Pfizer had two major updates that could significantly impact its […]
8 out of 10 Medical Device Companies Expect Medium or High Levels of Market Competition, According to Recent Survey from Cutting Edge Information
RESEARCH TRIANGLE PARK, NC–(Marketwired – May 05, 2015) – Medical device manufacturers face increasing competition as they move products through development and into a saturated market. According to a new report by primary intelligence provider Cutting Edge Information, 80% of surveyed medical device companies expect medium or high levels of market competition. Nearly half (49%) of […]
CARLSBAD, Calif., May 5, 2015 /PRNewswire/ — Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today reported pro forma operating income of $4.0 million for the three months ended March 31, 2015 compared to a pro forma net operating loss of $22.6 million for the same period in 2014. Isis’ significantly improved financial results were due to higher […]
MIAMI–(BUSINESS WIRE)–OPKO Health, Inc. (NYSE:OPK) is pleased to announce the acquisition of EirGen Pharma, Ltd., a growing, profitable and cash flow positive specialty pharmaceutical company focused on the development and commercial supply of high potency, high barrier to entry, pharmaceutical products for sale in the U.S., Canada, Japan, Australia, most European countries, and more than […]
“Reputation, built on our past, shapes our present and future. A good reputation can open many doors; a bad reputation can close many more. A good reputation generates respect. A bad reputation breeds suspicion.” Those are not the words of a business consultant or from a television talk show host like Dr. Phil. They are […]
(Reuters) – Fourteen U.S. and Canadian cancer institutes will use International Business Machines Corp’s (IBM.N) Watson computer system to choose therapies based on a tumor’s genetic fingerprints, the company said on Tuesday, the latest step toward bringing personalized cancer treatments to more patients. Oncology is the first specialty where matching therapy to DNA has […]
MOUNTAIN VIEW, CA–(Marketwired – May 05, 2015) – VIVUS, Inc. (NASDAQ: VVUS) (the “Company”), a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health, today provided a business update and reported its financial results for the first quarter ended March 31, 2015. “We have sharpened […]
As Hampton Takes Over as Chairman at GlaxoSmithKline (GSK), CEO Witty Needs to Deliver or “Step Aside”
GlaxoSmithKline (GSK) is under scrutiny Tuesday, after more analysts have called for its longstanding chief executive, Sir Andrew Witty, to either step up his performance or resign within the next year, as the company prepares to receive its new chairman later this week. “Mr. Witty is running out of time,” said Stephen Bailey, a fund […]